Department of Chemistry and Biomolecular Sciences Colloquium

Presented by Professor Michelle L. James
Friday, 26 October 2018 - 11:30 am to 1:00 pm
Location
Room number: 
214
Contact information
Contact person: 
Dept. of Chemistry and Biomolecular sciences
Email: 
chminfo@uottawa.ca
Phone: 
613-562-5728
Registration
Registration required: 
No
Cost to attend: 
Free of charge
Event organizer: 
Event language: 

The Department of Chemistry and Biomolecular Sciences is pleased to welcome Professor James from Stanford University.

Join us at 11:10 for refreshments followed by her lecture "The Power of PET Imaging: Revolutionizing detection and treatment of neurological diseases"

Biography

Dr. James is an Assistant Professor in the Departments of Radiology and Neurology, within the Molecular Imaging Program at Stanford (MIPS). She received her BS in pharmacology and medicinal chemistry at the University of Sydney, where she also earned her PhD in radiochemistry/neuropharmacology and was awarded the prestigious University Medal. For nearly fifteen years, Dr. James’s research has focused on developing and evaluating novel molecular imaging agents to improve the way we diagnose, treat, and understand brain diseases. In particular, she is interested in designing new positron emission tomography (PET) radioligands for visualizing the neuroinflammation – an area at the interface of chemistry, neurobiology, and immunology. Dr. James uses the radiolabeled molecules she develops to study the neuroimmune interactions underlying Alzheimer’s disease, multiple sclerosis, and stroke with the goal of learning about the in vivo role, spatiotemporal dynamics, and different functional phenotypes of specific innate and adaptive immune cells in the very early stages of these diseases and throughout their progression. Dr. James is also very interested in applying these tools to track disease progression, guide therapeutic selection for individual patients, and serve as surrogate endpoints in clinical trials. Dr. James has multiple patented radioligands for imaging neurological diseases, four of which are currently being evaluated in humans.